Medical and Pharmaceutical Industry - Market Research Report

Atypical Chemokine Receptor 3 (C-X-C Chemokine Receptor Type 7 or Chemokine Orphan Receptor 1 or G Protein Coupled Receptor 159 or G Protein Coupled Receptor RDC1 Homolog or GPR159 or CXCR7 or ACKR3) - Pipeline Review, H2 2016 Summary Radiant insights, inc, 'Atypical Chemokine Receptor 3 (C-X-C Chemokine Receptor Type 7 or Chemokine Orphan Receptor 1 or G Protein Coupled Receptor 159 or G Protein Coupled Receptor RDC1 Homolog or GPR159 or CXCR7 or ACKR3) - Pipeline Review, H2 2016', provides in depth analysis on Atypical Chemokine Receptor 3 (C-X-C Chemokine Receptor Type 7 or Chemokine Orphan Receptor 1 or G Protein Coupled Receptor 159 or G Protein Coupled Receptor RDC1 Homolog or GPR159 or CXCR7 or ACKR3) targeted pipeline therapeutics. The report provides comprehensive information on the Atypical Chemokine Receptor 3 (C-X-C Chemokine Receptor Type 7 or Chemokine Orphan Receptor 1 or G Protein Coupled Receptor 159 or G Protein Coupled Receptor RDC1 Homolog or GPR159 o...

Radiant insights, inc latest Pharmaceutical and Healthcare disease pipeline guide Liver Cancer - Pipeline Review, H2 2016, provides an overview of the Liver Cancer (Oncology) pipeline landscape. Liver cancer starts in the liver. The risk factors for liver cancer include hepatitis, cirrhosis, or scarring of liver, being male and having low weight at birth. Symptoms include a lump or pain on the right side of the abdomen and yellowing of the skin. Treatment of liver cancer may include chemotherapy, radiation and surgery. Report Highlights Radiant insights, inc Pharmaceutical and Healthcare latest pipeline guide Liver Cancer - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Liver Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete resear...

Radiant insights, inc latest Pharmaceutical and Healthcare disease pipeline guide Head And Neck Cancer Squamous Cell Carcinoma - Pipeline Review, H2 2016, provides an overview of the Head And Neck Cancer Squamous Cell Carcinoma (Oncology) pipeline landscape. Head and Neck Cancer Squamous Cell Carcinoma is a cancer that arises in the head or neck region (in the nasal cavity, sinuses, lips, mouth, salivary glands, throat, or larynx. The common symptoms of cancer of the head and neck include persistent pain in the throat, pain or difficulty with swallowing, persistent hoarseness or a change in voice, pain in the ear and bleeding in the mouth or throat. The disease may be controlled by chemotherapy and radiation therapy. Report Highlights Radiant insights, inc Pharmaceutical and Healthcare latest pipeline guide Head And Neck Cancer Squamous Cell Carcinoma - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Head And Neck Cancer Squ...

Radiant insights, inc, 'Apolipoprotein A I (APOA1) - Pipeline Review, H2 2016', provides in depth analysis on Apolipoprotein A I (APOA1) targeted pipeline therapeutics. The report provides comprehensive information on the Apolipoprotein A I (APOA1) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Apolipoprotein A I (APOA1) targeted therapeutics development and features dormant and discontinued projects. Radiant insights, inc report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Radiant insights, inc propriet...

Radiant insights, inc latest Pharmaceutical and Healthcare disease pipeline guide Aplastic Anemia - Pipeline Review, H2 2016, provides an overview of the Aplastic Anemia (Hematological Disorders) pipeline landscape. Aplastic anemia is a syndrome of bone marrow failure characterized by peripheral pancytopenia and marrow hypoplasia. Symptoms include fatigue, pale skin, rapid or irregular heart rate, shortness of breath with exertion, nosebleeds and bleeding gums, prolonged bleeding from cuts, skin rash, dizziness and headache. Risk factors include exposure to toxic chemicals, treatment with high-dose radiation or chemotherapy for cancer, certain blood diseases, autoimmune disorders and serious infections. Treatment includes immunosuppressants and stem cell transplant. Report Highlights Radiant insights, inc Pharmaceutical and Healthcare latest pipeline guide Aplastic Anemia - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Apl...